An­timi­cro­bial re­sis­tance biotech se­cures $37M with ex-Cure­Vac CEO Franz-Wern­er Haas at the helm

Three months in­to his role at the helm of GSK’s bac­te­r­i­al in­fec­tion spin­out Lim­maT­e­ch, Cure­Vac vet­er­an Franz-Wern­er Haas is fo­cused on scal­ing the com­pa­ny. And now he has an ex­tra $37 mil­lion to work with.

Lim­maT­e­ch an­nounced the fi­nanc­ing round ear­ly Mon­day morn­ing, led by Ad­ju­vant Cap­i­tal, AXA IM Alts and the No­vo Hold­ings RE­PAIR Im­pact Fund. Lim­maT­e­ch was found­ed in 2015, and clos­ing a Se­ries A sev­en years in­to a com­pa­ny’s life is “a bit ab­nor­mal,” Haas con­ced­ed. But the mon­ey will come in handy as the biotech looks to chart its own path out­side a re­search col­lab­o­ra­tion with GSK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER